· Executive Brief
Ovarian Cancer Awareness Month 2026
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership signal
Ovarian Cancer Awareness Month can serve as an executive operating checkpoint.
Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Ovarian cancer outcomes depend on the pathway before treatment
Ovarian cancer rarely announces itself clearly. Symptoms such as bloating, early satiety, pain and bowel or urinary changes are common and nonspecific, so patients may pass through several services before anyone suspects cancer.[5] Five-year survival is 90% for stage I disease but 15% for stage IV, and over 70% of patients worldwide are diagnosed at advanced stages.[5]
Those numbers turn ovarian cancer into an operating question as much as a clinical one. In Nova Scotia, 35.7% of people later diagnosed with epithelial ovarian cancer first presented at an emergency department.[4] Between first presentation and diagnosis, they saw a median of four physicians across a median of three specialties.[4] Each of those contacts is a handoff that can either move the patient forward or lose time.
The next steps are just as fragile. Only two-thirds of patients with ovarian cancer ever see a gynecologic oncologist, according to the authors of a recent referral pilot.[6] Guidelines recommend offering germline genetic testing to all patients diagnosed with epithelial ovarian cancer.[7] Yet at five regional cancer centers in Japan, only 25.3% of patients with ovarian cancer completed testing.[14] Families who could benefit from cascade testing are not reliably reached either; one traceback program reported 38% cascade uptake among at-risk relatives.[13]
Ovarian Cancer Awareness Month is a useful moment for leaders to ask where these steps break and who owns them. The answer is rarely a single department. Primary care, emergency medicine, imaging, gynecology, gynecologic oncology, genetics and navigation each hold part of the pathway. Clear ownership of each handoff matters more than the volume of awareness messaging.
The sections below summarize peer-reviewed evidence on diagnostic timing, referral, genetic testing, disparities, workforce and communication. They sit beside the executive guidance already on this page and give leaders a shared factual base for choosing where to act first.
Current evidence
What the research says about diagnostic timing and triage
Earlier studies often found no survival benefit from faster ovarian cancer diagnosis, which discouraged investment in diagnostic improvement. A North Carolina cohort of 2,359 women diagnosed from 2009 to 2019 tested whether that finding reflected a wait time paradox.[1] The median interval from the first symptom-related encounter to diagnosis was 33 days.[1] If faster diagnosis appeared useless only because of how earlier studies were analyzed, the case for diagnostic investment needs a fresh look.[1]
The relationship turned out to be U-shaped. Patients in the second-shortest quartile of diagnostic interval had a median survival exceeding five years, compared with 2.5 years in the shortest quartile and 2.9 years in the longest.[1] Compared with an 80-day reference, a 10-day interval was associated with higher mortality, with a hazard ratio of 1.29.[1] The authors judged the poor survival with very short intervals to be consistent with confounding by disease severity, while longer intervals were also associated with worse outcomes.[1]
For executives, the implication is that diagnostic speed still matters for patients whose disease is not already advanced. The Nova Scotia study found a median time to diagnosis of 30 days among 652 patients.[4] Factors associated with a long time to diagnosis included health zone, site of first presentation and continuity of care, all of which are features of how care is organized.[4] Leaders can examine where their own patients first present and how often they see the same clinician before diagnosis.
Triage accuracy is the second lever. A large UK research program recruited 2,453 women with symptoms, raised tumor markers or abnormal imaging across 23 hospitals.[5] In premenopausal women, the existing risk index at its standard threshold had a sensitivity of 42.6%, while an ultrasound-based model at a 10% threshold reached 89.1% with acceptable specificity.[5] In postmenopausal women, the same ultrasound model had the best sensitivity, at 96.1%.[5]
The program found that a two-step ultrasound strategy at the same sitting offered the best balance across cost and diagnostic yield.[5] Ultrasound in the study was performed by certified sonographers with quality assurance, which signals that test choice and staff training must change together.[5] Taken together, the evidence supports investment in faster, better-organized diagnosis rather than acceptance of late detection. Diagnostic improvement is therefore a design task for imaging, primary care and gynecology together.
Figure 1
Ovarian cancer pathway steps reach only part of the eligible population
Percent of eligible patients or relatives completing each pathway step, as reported in each study. Values are copied from the cited studies [6], [13], [14]; none is estimated.
Data note. These values come from different countries, health systems and pathway steps, so this is an indirect comparison; the bars show where the pathway thins, not how one step compares with another.
Limitation. Each value reflects its own setting and denominator; the referral figure is from a small pilot with a historical comparison.
Figure data (4 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Referred to gynecologic oncology within 90 days with a clinician nudge | 75% | Patients with high-risk adnexal imaging in a 2024 single-system pilot; historical baseline 61% | [6] |
| Received hereditary cancer information from a gynecologist | 66.4% | 229 patients with ovarian cancer at five regional cancer centers in Japan, 2021 to 2022 | [14] |
| At-risk relatives completing cascade testing | 38% | Relatives eligible after traceback testing in a U.S. health system study | [13] |
| Patients with ovarian cancer completing genetic testing | 25.3% | Same Japanese multicenter cohort | [14] |
Continuum of care
Where the pathway breaks between suspicion, specialist care and family testing
The transition from suspicious imaging to a gynecologic oncologist is one of the clearest failure points. A 2024 pilot sent an electronic health record nudge with a pended referral order to primary care, emergency and gynecology clinicians within two business days of high-risk imaging.[6] The 90-day referral rate was 75%, compared with a historical baseline of 61%.[6]
The same pilot reported that 92% of patients undergoing surgery for complex adnexal masses had that surgery with gynecologic oncology, compared with 82% at baseline.[6] One in four patients in the pilot were diagnosed with cancer, all at an early stage.[6] The study was small, with 20 nudges sent, but it suggests that a default referral may help close a gap that depends on individual memory.[6] The authors said a randomized trial is warranted, so leaders should treat the result as promising rather than settled.[6]
Specialist care is associated with treatment that follows guidelines. A national analysis of ovarian cancer cases from 2005 to 2015 found lower guideline concordance among Black patients with epithelial tumors.[12] After adjustment, Black patients had a higher risk of death than White patients, with a hazard ratio of 1.15, which fell only slightly to 1.13 when guideline-concordant treatment was included.[12] The authors concluded that other unmeasured factors likely influence outcomes as well.[12] Concordance remains a useful governance measure, but it should be reviewed together with referral and stage at diagnosis.
Genetic testing creates a second continuum that extends beyond the patient. In a Japanese multicenter study of 229 patients with ovarian cancer, 66.4% received information about hereditary cancer syndromes from their gynecologists.[14] Only 26.6% then received genetic counseling and 25.3% completed testing.[14] Among patients flagged as high risk through tumor profiling, 27.6% did not undergo genetic testing.[14] Each drop between information, counseling and testing is a handoff that a navigator or default order could support.
Late testing reduces the preventive value of the result. In a Canadian cohort of 476 carriers of hereditary cancer variants, nearly 70% of primary cancers were already diagnosed at the time of testing.[11] Older age at referral was associated with higher odds of developing cancer, with an odds ratio of 1.07 per year.[11] The authors called for system-level initiatives to promote earlier testing, cascade outreach and stronger surveillance pathways.[11]
Figure 3
Why the pathway breaks
People
- Too few gynecologic oncologists in underserved areas
- Limited genetic counseling capacity
- Sonographers not trained in newer triage models
Process
- No default referral after high-risk imaging
- Genetic testing offered inconsistently after diagnosis
- Single conversation about sharing results with relatives
Technology
- No electronic prompt to refer suspicious imaging
- Results not tracked across emergency, primary and specialty care
- No registry of untested past patients
Environment
- First presentation in emergency departments
- Distance to specialist centers
- Multiple specialties seen before diagnosis
Policy
- Out-of-pocket cost for genetic testing
- Affordability limits on specialist access
- Late referral for hereditary risk assessment
Measurement
- Time to diagnosis not measured
- Referral and concordance not stratified by race or income
- Cascade testing completion not tracked
Unranked qualitative cause-and-effect diagram for the outcome in the box: Patients with ovarian cancer are diagnosed late, miss gynecologic oncology care or genetic testing, and at-risk relatives are not tested Causes are assembled from the cited literature [2], [3], [4], [5], [6], [8], [9], [11], [13], [14], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Too few gynecologic oncologists in underserved areas; Limited genetic counseling capacity; Sonographers not trained in newer triage models |
| Process | No default referral after high-risk imaging; Genetic testing offered inconsistently after diagnosis; Single conversation about sharing results with relatives |
| Technology | No electronic prompt to refer suspicious imaging; Results not tracked across emergency, primary and specialty care; No registry of untested past patients |
| Environment | First presentation in emergency departments; Distance to specialist centers; Multiple specialties seen before diagnosis |
| Policy | Out-of-pocket cost for genetic testing; Affordability limits on specialist access; Late referral for hereditary risk assessment |
| Measurement | Time to diagnosis not measured; Referral and concordance not stratified by race or income; Cascade testing completion not tracked |
Access
Making specialist care and genetic services reachable
Access to gynecologic oncology varies with the structure of care around the patient. A study of 8,987 Medicare patients aged 65 or older with ovarian cancer built composite scores for health care affordability, availability and accessibility.[15] Higher availability and affordability were each associated with gynecologic oncologist consultation, with adjusted odds ratios of 1.16 and 1.13.[15] Affordability was also associated with receipt of ovarian cancer surgery.[15] These dimensions are features of the system, which means leaders can influence them through location, coverage and scheduling decisions.
Geography shapes the same picture nationally. An analysis of 1,398,959 people diagnosed with gynecologic cancers from 2001 to 2019 examined late-stage diagnosis by race, social vulnerability and county-level access to gynecologic oncologists.[2] The authors concluded that poor geographic access to specialty care, along with race, ethnicity and social vulnerability, drives disparities in stage at diagnosis.[2] They called for workforce expansion in underserved areas.[2]
Genetic services can be brought to patients rather than waiting for referral. Traceback programs contact patients previously diagnosed with ovarian cancer who were never tested. Across three large U.S. health systems, the share of identified living patients who had never been tested ranged from 25.5% to 62.1%.[8] Of those untested patients, between 8.0% and 33.0% went on to complete genetic testing.[8] A list of past patients who were never tested is a practical starting point for any health system with a cancer registry.
Cost and logistics determine who completes testing. A pilot trial enrolled 60 probands and 144 at-risk relatives, and 68.8% of relatives reported at least one structural barrier to care.[3] Cascade testing was completed by 3.4% of relatives with usual care and 20.5% with self-initiated no-cost telegenetic services.[3] It rose to 56.7% with proactive navigator support and a bilingual digital platform, and 78.3% when navigation was combined with no-cost telegenetic testing.[3] The gradient across arms suggests that removing cost alone helps, but proactive navigation adds far more.[3]
Out-of-pocket price is a barrier in many systems. In Malaysia, 58% of 100 patients with ovarian cancer stated a willingness to pay for genetic testing, but only 17% took the test at full price.[9] Affordability was the most common reason for being unwilling to pay, cited by 71%.[9] Executives can treat cost coverage for testing as part of access design rather than a patient decision.
Executive guidance · System route
Build one visible operating route for Ovarian Cancer Awareness Month.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Navigate across services
Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Navigate across services | Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Who reaches specialist care and who is left behind
Racial and ethnic differences in ovarian cancer care appear at the referral step. In the Medicare cohort, Black patients were less likely than White patients to consult a gynecologic oncologist, with an adjusted odds ratio of 0.75.[15] Hispanic patients were also less likely to consult one, at 0.81.[15] Black patients were less likely to receive surgery, with an adjusted odds ratio of 0.76.[15]
Those gaps were not fully explained by access. After mutual adjustment for affordability, availability and accessibility, Black patients remained less likely to consult a gynecologic oncologist and to receive surgery, with adjusted odds ratios of 0.80 for each.[15] The national gynecologic cancer analysis likewise found late-stage diagnosis significantly more likely among non-Hispanic Black women across all cancer types studied.[2] The authors recommended culturally tailored early detection programs alongside workforce expansion.[2] Disparities that persist after access is accounted for point to referral practices, communication and trust as additional targets.
Income shapes genetic testing as well. In a Chinese study of 154 patients with epithelial ovarian cancer, 64.94% underwent germline testing.[7] Higher household income was associated with testing, with an odds ratio of 3.30, and high awareness of testing was associated with an odds ratio of 8.81.[7] Most patients, 62.99%, had low awareness of germline testing.[7] When awareness and income drive uptake, a default offer with financial support is an equity measure. Low awareness was common enough that education alone may not close the gap without a structured offer.
Family testing has its own disparities. In a U.S. traceback study, cascade testing uptake among at-risk relatives was 38%, and women were more likely to complete testing than men, at 45% versus 30%.[13] Relatives who carry a variant but are not tested lose the chance of targeted prevention. Navigation that reaches men and distant relatives deserves attention in program design. Tracking cascade completion by sex and degree of relationship shows where outreach is falling short.
Trust underpins all of these steps. The navigator-supported trial recruited a community cohort in which most relatives faced structural barriers, and informed decision-making reached 80.0% in the navigation arms compared with 14.0% in the others.[3] Equity reviews should stratify referral, treatment concordance and testing measures by race, ethnicity, income and geography, and share what they find with the communities affected.
Human infrastructure
The people who carry patients from suspicion to specialist care
Ovarian cancer pathways depend on a small number of specialized roles. Gynecologic oncologists, sonographers, genetic counselors, navigators and the primary care and emergency clinicians who first see symptoms all shape the outcome. When any of these roles is scarce, the effect shows up as delay or missed referral rather than visible failure. Each role also needs backup coverage, because a single absent counselor or navigator can stall testing for weeks.
Specialist supply is a structural constraint. The national gynecologic cancer analysis linked poor geographic access to gynecologic oncologists with late-stage diagnosis and called for expanding that workforce in underserved areas.[2] Health systems can extend reach through outreach clinics, telehealth consultation and clear referral agreements with regional centers. Referral agreements should name the receiving clinic, the expected time to first visit and how results return to the referring clinician.
Imaging staff are part of diagnostic quality. The UK triage program recommended an ultrasound model as the new standard for women with suspected ovarian cancer and stressed that implementation should include staff training and quality assurance.[5] A better test produces better triage only when sonographers are trained and audited to use it consistently.[5] Quality assurance data also show leaders where retraining or added sonographer capacity is needed.
Genetic counseling capacity is often the bottleneck. Earlier work in Malaysia found that training oncologists to provide genetic counseling raised testing uptake to 80% when the test was free.[9] In the Japanese study, the authors identified inadequate provider communication as a primary barrier to testing.[14] Training gynecologists and oncologists to offer counseling, with genetic specialists supporting complex cases, extends a scarce workforce.[9]
Navigators make the family pathway work. In the trial of navigator support, the arms with proactive family genetic navigators had much higher cascade testing completion than those without, with an odds ratio of 26.9.[3] Traceback programs also depend on staff time: program costs ranged from $41,564 to $120,327 across three health systems, with the lowest cost per patient tested at $1626.[8] Budgeting these roles as part of the cancer program, rather than as pilot funding, keeps the pathway open. Knowing cost per patient tested helps leaders compare program designs and plan staffing realistically.[8]
Executive guidance · Operating dashboard
Use a small dashboard to expose friction and ownership.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Navigation continuity
Where does ownership become unclear as people move among information, evaluation, services, and follow-through?
- Candidate local measure
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Navigation continuity | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Close the loop across teams, settings, and partners.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the receiving service and confirm acceptance without promising a clinical determination or outcome.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Give leaders one view of route reliability and improvement.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Navigation continuity | Where does ownership become unclear as people move among information, evaluation, services, and follow-through? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable ovarian cancer pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Default referral after high-risk adnexal imaging | Patients never reach gynecologic oncology | Chief medical officer with radiology and gynecologic oncology leads | Share of high-risk imaging results referred within 90 days |
| Trained and audited ultrasound triage | Cancers missed or benign masses overtreated | Imaging director | Sonographer training completion and quality assurance audits |
| Diagnostic interval tracking from first symptomatic visit | Long, fragmented diagnostic journeys go unseen | Cancer center administrator | Median time to diagnosis by site of first presentation |
| Genetic counseling and testing offered to every patient | Hereditary variants go undetected | Gynecologic oncology lead with genetics program | Share of patients counseled and tested within a set interval |
| Traceback and cascade testing outreach | Past patients and relatives miss prevention | Genetics program manager with navigation lead | Untested patients contacted and relatives tested |
| Stratified concordance and access reporting | Racial and income disparities persist unseen | Board quality committee with health equity lead | Consultation, surgery and concordant care by subgroup |
Control points derived from the cited evidence [3], [4], [5], [6], [8], [12], [13], [14], [15] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating risk and next steps in ways patients and families trust
Ovarian cancer awareness messages carry a particular risk of false reassurance or unnecessary alarm, because symptoms are common and nonspecific. The UK triage program found that cancer diagnosis rates were very low, at 1.6%, in women under 40, yet high anxiety and distress were noted, particularly in younger women.[5] Communication should explain the diagnostic pathway and what happens next, not only list symptoms. Messages that explain how to reach the right clinic, and what to expect there, are more useful than symptom lists alone.
Clinician communication matters as much as public messaging. In the Japanese multicenter study, 38% of patients with ovarian cancer who received information about hereditary syndromes from their gynecologists went on to complete testing.[14] Patient disinterest was the main barrier among high-risk individuals, and the authors linked low uptake to inadequate provider communication.[14] Scripts, decision aids and a default offer of counseling help clinicians present testing consistently. Clinicians who discuss testing as routine care, not as an optional extra, may reduce the sense that it is a special request.
Families need help sharing genetic results. In the U.S. traceback study, only two probands initially consented to direct contact with at-risk relatives by the study genetic counselor.[13] Six more requested direct contact over later interactions, which suggests that willingness to accept direct contact can change over repeated interactions.[13] Programs should offer letters, counselor contact and follow-up rather than relying on a single conversation. Navigators can schedule these follow-up conversations rather than waiting for families to ask.
Prevention decisions also follow communication. Among 138 Thai women with breast cancer and germline BRCA variants, 58.7% underwent risk-reducing surgery to remove the ovaries and fallopian tubes.[10] Ovarian cancer was detected in 7.4% of those who had surgery, and the median interval from genetic testing to surgery was 8 months.[10] The authors recommended understanding reasons for refusal and offering alternative prevention strategies.[10]
Public reporting can build trust when it is honest about limits. Referral rates, time to diagnosis, guideline-concordant treatment and genetic testing completion are measurable and meaningful to patients.[6][11] Reporting them with definitions, stratified by population, shows the community that awareness is matched by a reliable pathway. Sharing those results with clinicians in primary care and emergency medicine also reinforces their role at the start of the pathway.
Executive guidance · 90-day plan
Turn the observance into one sustained operating change.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Ovarian Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Ovarian Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Make Ovarian Cancer Awareness Month a starting point, not an endpoint.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Make ownership visible, test the route, and report what improved.
Executive action kit · Month observance
Turn Ovarian Cancer Awareness Month into accountable action.
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, diagnostic navigation, support, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review whether language, transportation, cost, digital access, disability, geography, or trust changes a person’s ability to complete the locally approved route.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, caregivers, navigation teams, clinical services, and community partners. Find one a confusing entry point, unowned transition, or unresolved navigation need, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During Ovarian Cancer Awareness Month, our organization will connect awareness with a practical review of the information, diagnostic navigation, support, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Ovarian Cancer Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Soppe SE, Kuo TM, Bae-Jump VL, Albright BB, Lyratzopoulos G, Baggett CD, et al. Diagnostic Timing and Ovarian Cancer Survival. JAMA Network Open. 2026;9(3):e262434. https://doi.org/10.1001/jamanetworkopen.2026.2434
- 2.Desjardins MR, Desravines N, Patel V, Leath CA, Stone R, Curriero FC, et al. Trends in US gynecologic cancers (2001–2019): influence of social determinants, geographic disparities, and specialist access on stage at diagnosis. American Journal of Obstetrics and Gynecology. 2026. https://doi.org/10.1016/j.ajog.2026.08.020
- 3.Jorgensen KA, Agusti N, Coffin T, Barajas K, Iniesta MD, Bednar EM, et al. A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment. JAMA Network Open. 2026;9(8):e2630668. https://doi.org/10.1001/jamanetworkopen.2026.30668
- 4.Gottheil C, Woolcott C, Marshall EG, Kieser K, Urquhart R. Examining the diagnostic process for ovarian cancer in Nova Scotia: A linked administrative data study. International Journal of Gynecology & Obstetrics. 2026:ijgo.71149. https://doi.org/10.1002/ijgo.71149
- 5.Sundar S, Agarwal R, Scandrett K, Davenport C, Sturdy L, Ottridge R, et al. Identifying the best diagnostic test for ovarian cancer – synopsis of Refining Ovarian Cancer Test accuracy Scores (ROCkeTS) research. Health Technology Assessment. 2026:1-21. https://doi.org/10.3310/bdhs6485
- 6.Smith AJB, Mehta SJ, Cook T, Chambers C, Rochester S, Zafar H, et al. Clinician Nudge to Gynecologic Oncology Referral at Suspected Ovarian Cancer Diagnosis: A Pilot Study. Cancer Control. 2026;33:10732748261424959. https://doi.org/10.1177/10732748261424959
- 7.Wang X, Cai HY, Lin LH, You J, Zhao YJ, Chen XM, et al. Awareness, uptake, and determinants of germline genetic testing in Chinese epithelial ovarian cancer patients: a cross-sectional study. Frontiers in Oncology. 2026;16:1876816. https://doi.org/10.3389/fonc.2026.1876816
- 8.Hassen D, Buchanan AH, Henrikson NB, Jonas MC, Leppig KA, Leitzel T, et al. Evaluation of Costs, Efficiency and Performance of a Pilot Genetic Testing Traceback Program for Ovarian Cancer. Cancers. 2026;18(14):2292. https://doi.org/10.3390/cancers18142292
- 9.Padmanabhan H, Lim KK, Hassan NT, Ahmad Bashah NS, Lee YQ, Lim J, et al. Exploring willingness to pay out-of-pocket for genetic testing among ovarian cancer patients in Malaysia, a middle-income country in Asia. Journal of Gynecologic Oncology. 2026;37(3):e32. https://doi.org/10.3802/jgo.2026.37.e32
- 10.Pradutchon S, Pithukpakorn M, Poonyakanok V. The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants. European Journal of Cancer Prevention. 2026;35(5):457-464. https://doi.org/10.1097/cej.0000000000001005
- 11.Etchegary H, Puddester R, Gao Z, Francis V, Warren M, Burry TN, et al. Suboptimal Adherence to Hereditary Cancer Risk Management Guidelines: A Cohort Study of High-Risk Individuals in Newfoundland and Labrador, Canada. Current Oncology. 2026;33(4):184. https://doi.org/10.3390/curroncol33040184
- 12.Barragan M, David SM, Chen Z, Richardson K, Qiang W, Miodragovic D, et al. Assessment of national cancer care network guideline-adherent treatment differences as a contributor to racial disparities in epithelial and non-epithelial ovarian cancer survival. Cancer Treatment and Research Communications. 2026;48:101307. https://doi.org/10.1016/j.ctarc.2026.101307
- 13.Zepp JM, Feigelson HS, Prado YK, Reyes AA, Rope AF, Sawyer JK, et al. Cascade testing in an ovarian cancer traceback genetic testing program: The GRACE study experience. Journal of Genetic Counseling. 2025;34(6):e70133. https://doi.org/10.1002/jgc4.70133
- 14.Yokoyama T, Yamamoto Y, Okazawa-Sakai M, Yamashita N, Usami T, Matsumoto M, et al. Current management of hereditary cancer syndromes in ovarian and endometrial cancer: a Japanese study. Japanese Journal of Clinical Oncology. 2025;56(2):180-186. https://doi.org/10.1093/jjco/hyaf176
- 15.Gupta A, Chen Q, Wilson LE, Huang B, Pisu M, Liang M, et al. Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation. JAMA Network Open. 2023;6(2):e2254595. https://doi.org/10.1001/jamanetworkopen.2022.54595
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Stage-dependent survival and diagnostic triage accuracy | [5] | 2026 | Current evidence | UK research program in secondary care; test performance depends on trained sonographers and local prevalence. |
| Diagnostic interval and survival | [1] [4] | 2026 | Current evidence | Registry and claims data in one U.S. state and one Canadian province; confounding by disease severity. |
| Referral to gynecologic oncology | [6] [15] | 2026, 2023 | Continuum of care | Small single-system pilot with historical comparison; Medicare cohort aged 65 or older. |
| Guideline-concordant treatment and racial disparities | [12] [15] [2] | 2026, 2023 | Equity and trust | Retrospective national data; missing stage and surgical detail; associations not causal. |
| Genetic testing uptake and barriers | [14] [7] [9] | 2026, 2025 | Continuum of care | Single-country cross-sectional studies in Japan, China and Malaysia. |
| Traceback and cascade testing programs | [8] [13] [3] | 2026, 2025 | Access | Nonrandomized pilots and a small pilot trial; cascade outcomes measured over limited follow-up. |
| Hereditary risk management and prevention | [10] [11] | 2026 | Public communication | Single-center Thai cohort and Canadian provincial cohort with late referral. |
About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.